Bio-Rad Laboratories (BIO-B) Net Income towards Common Stockholders (2009 - 2026)

Bio-Rad Laboratories (BIO-B) has 18 years of Net Income towards Common Stockholders data on file, last reported at -$527.1 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders fell 923.59% year-over-year to -$527.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $168.8 million (up 107.8% YoY) and the FY2025 annual result came in at $759.9 million, up 141.2% from the prior year.
• Net Income towards Common Stockholders fell to -$527.1 million in Q1 2026 per BIO-B's latest filing, from $720.0 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $827.8 million in Q4 2022 and bottomed at -$3.4 billion in Q1 2022.
• The 5-year median for Net Income towards Common Stockholders is $64.0 million (2025), against an average of -$345.7 million.
• The widest annual swing landed in 2024, when Net Income towards Common Stockholders soared 514.75%; it then sank 923.59% in 2026.
• Tracing BIO-B's Net Income towards Common Stockholders over 5 years: stood at $827.8 million in 2022, then plunged by 57.75% to $349.7 million in 2023, then plunged by 304.67% to -$715.8 million in 2024, then surged by 200.59% to $720.0 million in 2025, then tumbled by 173.21% to -$527.1 million in 2026.
• Per Business Quant, the three latest BIO-B Net Income towards Common Stockholders figures stand at -$527.1 million (Q1 2026), $720.0 million (Q4 2025), and -$341.9 million (Q3 2025).

Peer Comparison